Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 11th annual conference of the European Mantle Cell Lymphoma Network

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 699-707

  Dreyling, Martin ^a   Kluin Nelemans, Hanneke C ^b   Beà, Sílvia ^c   Klapper, Wolfram ^d   Vogt, Niclas ^d   Delfau Larue, Marie Helene ^e   Hutter, Grit ^f   Cheah, Chan ^g   Chiappella, Annalisa ^h   Cortelazzo, Sergio ⁱ   Pott, Christiane ^d   Hess, Georg ^j   Visco, Carlo ^k   Vitolo, Umberto ^h   Klener, Pavel ^l   Aurer, Igor ^m   Unterhalt, Michael ^a   Ribrag, Vincent ⁿ   Hoster, Eva ^a   Hermine, Olivier ^o  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF KIEL   (Germany)

^e HENRI MONDOR HOSPITAL   (France)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ CENTRAL HOSPITAL OF BOLZANO   (Italy)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k SAN BORTOLO HOSPITAL   (Italy)

^l CHARLES UNIVERSITY   (Czech Republic)

^m UNIVERSITY OF ZAGREB   (Croatia)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Chemotherapy; Mantle cell lymphoma; Molecular pathogenesis; Rituximab maintenance; Transplantation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FOSTAMATINIB; IBRUTINIB; IDELALISIB; ISOSORBIDE; LENALIDOMIDE; MCL 0208; MELPHALAN; NAVITOCLAX; NPI 0054; OBATOCLAX; OLAPARIB; PALBOCICLIB; PREDNISONE; RG 7112; RITUXIMAB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MEGADOSE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; THALIDOMIDE;

EID: 84879533106     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.733882     Document Type: Review

References (42)

1. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profi ling. Blood 2005; 106: 4315-4321.
2. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007; 25: 1216-1222.
3. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profi ling. Blood 2010; 116: 953-961.
4. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008; 111: 5683-5690.
5. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly Specific for mantle cell lymphoma and identifi es the cyclin D1-negative subtype. Haematologica 2009; 94: 1555-1562.
6. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, et a l. Diff erential diagnosis of cyclin D2 + mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 2009; 94: 1595-1598.
7. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385-2387.
8. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009; 2: 103-111.
9. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149-165.
10. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
11. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to six courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCLnet). Blood 2010; 116(Suppl. 1); Abstract 110.
12. Jardin F, Picquenot JM, Parmentier F, et al. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: Clinicopathological relevance and prognosis value. Br J Haematol 2009; 146: 607-618.
13. Delfau-Larue MH, Hoster E, Jardin F, et al. High dose aracytine in induction might counteract the adverse prognostic value of gene copy number alteration in autografted MCL patients. A EUMCL network study. Ann Oncol 2011; 22(Suppl. 4): Abstract 234.
14. Pé r ez-Galá n P, Dreyling M, Wiestner A. M antle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26-38.
15. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010: 265-270.
16. Castillo JJ, Furman M, Winer ES. CAL-101: A phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012; 21: 15-22.
17. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
18. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
19. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896-3902.
20. Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Anna Oncol 2008; 19: 135-141.
21. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78: 145-149.
22. Valdez R, Kroft SH, Ross CW, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002; 15: 1073-1079.
23. Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: Frequency and clinical features. Br J Haematol 2009; 147: 83-88.
24. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
25. Navarro A, Campo E. N ew perspective and challanges in the understanding of mantle cell lymphoma. Ann Oncol 2011; 22(Suppl. 4): Iv32-iv35.
26. Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifi es subsets of mantle cell lymphoma: Correlation to overall survival. Br J Haematol 2008; 143: 248-252.
27. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profi ling defi nes indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
28. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, asingle center experience. Bone Marrow Transplant 1998; 22: 645-650.
29. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin''s lymphoma. Ann Oncol 2011; 22: 1622-1627.
30. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (r-HDS regimen). Blood 2003; 102: 749-755
31. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study. Blood 2010; 115: 3215-3223.
32. Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 2011; 48: 208-213.
33. van der Velden VH, Panzer-Gr ü mayer ER, Cazzaniga G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706-713.
34. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740-4746.
35. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 2011; 12: 361-368.
36. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profi le in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
37. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas. First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2007; 110(Suppl. 1): Abstract 385.
38. Visco C, Castegnaro S, Chieregato K, et al. The cytotoxic Effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 2012; 48: 68-75.
39. Visco C, Zambello R, Paolini R, et al. Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Blood 2011; 118(Suppl. 1): Abstract 2677.
40. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269-2271.
41. Wang M, Fayad L, Wagner-Bartak N, et al. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: A completed phase I/II clinical trial. Ann Oncol 2011; 22(Suppl. 4): Abstract 109.
42. Harel S, Bachy E, Haioun C, et al. Efficacy and safety of thalidomide in mantle cell lymphoma: Results of the French ATU program. Blood 2010; 118(Suppl. 1): Abstract 4501.